XOMA - XOMA CorporationAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $24.93 | Open | |
| Volume | Market Cap | 158.61M | |
| Yield | Last Dividend |
| XOMA Reports Second Quarter 2020 Financi... | 08/06/20 |
| Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts | |
| XOMA Announces Natasha Hernday Joins its... | 07/01/20 |
| EMERYVILLE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President,??? | |
| XOMA joins Russell 2000 and 3000 Indexes... | 06/29/20 |
| XOMA Corporation (NASDAQ:XOMA) has been added to the Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closed on June 26, 2020. ?... | |
| XOMA Added to the Russell 2000?? and Rus... | 06/29/20 |
| EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000??... | |
| Xoma (XOMA) Reports Q1 Loss, Lags Revenu... | 05/05/20 |
| Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clue... | |
| Earnings Preview: Xoma (XOMA) Q1 Earning... | 04/27/20 |
| Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ... | |
| XOMA Reports Fourth Quarter and Full-Yea... | 03/10/20 |
| XOMA Corporation announced its fourth quarter and full-year 2019 financial results and business highlights. The post XOMA Reports Fourth Quarter and F... | |
| Xoma teams up with Zydus Cadila in cance... | 03/09/20 |
| XOMA (XOMA -7%) will collaborate with Zydus Cadila to develop an immuno-oncology drug candidate the combines the latter's IL-2 with XOMA's anti-IL-2 m... | |
| Xoma (XOMA) May Report Negative Earnings... | 02/27/20 |
| Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ... | |
| XOMA to Present at the Cowen and Company... | 02/25/20 |
| EMERYVILLE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will pres... | |
| The Daily Biotech Pulse: Endo's Cellulit... | 11/20/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) ... | |
| The Daily Biotech Pulse: Therapix To Rev... | 11/19/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) ... | |
| The Daily Biotech Pulse: Amarin Gets Una... | 11/15/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) ... | |
| The Daily Biotech Pulse: Amarin Braces F... | 11/14/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) A... | |
| The Daily Biotech Pulse: Merck Goes Shop... | 11/13/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ... | |
| Brokerages Expect XOMA Corp (NASDAQ:XOMA... | 11/12/19 |
| Brokerages expect XOMA Corp (NASDAQ:XOMA) to post ($0.28) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Resea... | |
| The Daily Biotech Pulse: Therapix Calls ... | 11/08/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs N... | |
| Xoma (XOMA) Reports Q2 Loss, Tops Revenu... | 08/06/19 |
| Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to... | |
| Analysts Estimate Xoma (XOMA) to Report ... | 07/30/19 |
| Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ... | |
| XOMA Corporation: Royalty Aggregation St... | 05/15/19 |
| No summary available. | |
| Xoma (XOMA) Surpasses Q1 Earnings and Re... | 05/06/19 |
| Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues... | |
| XOMA beats by $0.08, beats on revenue | 05/06/19 |
| No summary available. | |
| Will Xoma (XOMA) Report Negative Q1 Earn... | 05/01/19 |
| Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ... | |
| XOMA (XOMA) Presents At Cowen And Compan... | 03/12/19 |
| No summary available. | |
| XOMA reports Q4 results | 03/07/19 |
| No summary available. | |
| Xoma receives $5.5M from licensee Rezolu... | 02/13/19 |
| No summary available. | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
